Dax © 24.290 -0,33%
Dow Jones 44.326 0
S&P 500 6.297 -0,01%
Dow Jones 44.326 0
S&P 500 6.297 -0,01%
Nasdaq 23.055 +0,00%
Nikkei 39.690 +0,00%
Hang Seng 24.826 +1,33%
Nikkei 39.690 +0,00%
Hang Seng 24.826 +1,33%
EUR/USD 1,16259 +0,27%
BTC/USD 118.157 +0,13%
ETH/USD 3.564 +0,45%
BTC/USD 118.157 +0,13%
ETH/USD 3.564 +0,45%
US-Tradingchancen
- Ersteller Kesso
- Erstellt am
- Tagged users Kein(e)
von lucky entdeckt
im moment deutet sich noch nichts an, aber da könnte mal was gehen, ist viel platz nach oben.
[url=http://peketec.de/trading/viewtopic.php?p=628108#628108 schrieb:tgler schrieb am 30.03.2009, 19:48 Uhr[/url]"]eli
sollte heute/morgen/übermorgen drehen
Ziel ,18 - ,20
csar
hab eingekauft,
muss aber über der ,14 schließen, besser bei ,15
[url=http://peketec.de/trading/viewtopic.php?p=628109#628109 schrieb:tgler schrieb am 30.03.2009, 19:49 Uhr[/url]"]Traumchart,
leider nicht früher aufgefallen,
klares Jahreshoch heute,
Kaufe ich bei Schwäche nach
[url=http://peketec.de/trading/viewtopic.php?p=627863#627863 schrieb:tgler schrieb am 30.03.2009, 15:43 Uhr[/url]"]USA zieht an
[url=http://peketec.de/trading/viewtopic.php?p=627745#627745 schrieb:
wow, es gibt im Moment massenhaft viel versprechend aussehende US-Charts...
Freitag sind die durch die Bank extremst gebeutelten Real Investment Trust (REITS) durch die Decke gegangen.
Viele Werte haben, obwohl sie bis Ende Dezember 2008 und seit Beginn der US-Immokrise bis zu 80% an Marktkapitalisierung verloren haben, teilweise bis Anfang März 2009 noch mal 30-50% abgegeben.
Verrückte kranke shice.
Der führende US-Shopping Center Entwickler Kimco, ist am Freitag und nach einem upgrade von sell auf hold durch S&P Analyst Robert McMillan, mit +25,5% unter extrem hohem Volumen geradezu explodiert
und hat somit die gesamte REIT Branche nach oben gezogen.
Reit Index + 9.1 percent.
Man muss jedoch das Schlachthausniveau beachten .... Derzeit mit 2,5 Milliarden Dollar MK noch der grösste in der Branche (Bereich Shopping Center)
Kimco 9,40 + 25,50
Weingarten
11,33
Simon Properties 41,30
Boston Properties mit einem interssanten Chart
41,69
desgleichen AMB Properties
17,86
Pro Logis als weltweit grösster Logistic Space Entwickler und Betreiber dürfte auch wieder drehen . kommt von 60 Dollar !!!
Equity Residential 21,67
UPDATE 2-Strong demand for Kimco shares raises REITs
Fri Apr 3, 2009 6:17pm EDT
* Strong demand prompts company to boost offering
* Shares rise 25.5 percent
* REIT Index up 9.1 percent.
By Ilaina Jonas
NEW YORK, April 3 (Reuters) -
Shares of shopping center owner Kimco Realty Corp KIM.N closed up 25.5 percent on Friday after strong demand for its stock offering prompted the company to increase the number of shares offered, lifting the badly beaten real estate investment trust (REIT) sector.
Kimco sold 91.5 million shares, up from the previously expected 70 million, after demand was stronger than expected. The shares were offered at $7.10 each.
After the close of the market, the company said its underwriters exercised an option to sell an additional 13.725 million shares, up from the previously planned 10.5 million over-allotment,
The credit crisis has pummeled REIT stocks, with investors concerned that the companies may not be able to refinance their sizable debts when they mature.
After falling 41.5 percent last year, the benchmark MSCI U.S. REIT Index .RMZ was down another 29.9 percent before Friday's pop of 9.1 percent.
"The market is seeing that the capital markets aren't closed," Raymond James analyst R.J. Milligan said. "It's a positive in the fact that investors are still willing to inject capital into REITS (real estate investment trusts).
All together, the offering is expected to net Kimco $717.3 million, to repay debt and for general corporate purposes.
Kimco shares rose $1.91 to close at $9.40 on the New York Stock Exchange, where they were among the top 10 percentage gainers. The company has a stake in about 1,950 properties in 45 U.S. states, Puerto Rico, Canada, Mexico and South America.
S&P analyst Robert McMillan raised his rating on Kimco shares to "hold" from "sell," early in the morning, based in part on the cash expected to be raised from the equity offering.
The optimism was contagious as shares of most property REITs rose.
Developers Diversified Realty CorpDDR.N closed at $2.71 cents, up 14.4 percent, or 34 cents. Macerich Co MAC.N closed up 22.4 percent, or $1.80 at $9.84. Pennsylvania Real Estate Investment Trust (PEI.N: Quote, Profile, Research, Stock Buzz) rose 18.4 percent, or 76 cents, to $4.90.
Boston Properties Inc BXP.N rose 12.4 percent, or $4.59 at $41.69 Federal Realty Investment Trust FRT.N rose $2 or 4.1 percent to close at $50.81. Simon Property Group Inc SPG.N rose 11.7 percent, or $4.33, to $41.30.
The net proceeds from the offering, along with its $394 million in cash and securities and about $1 billion available on its credit facility at the end of 2008, gives Kimco a leg up on meeting its $1.3 billion in debt maturities this year and next, McMillan said.
In the debt-constrained market, several other REITs such as AMB Property Corp (AMB.N: Quote, Profile, Research, Stock Buzz), Simon, and Alexandria Real Estate Equities Inc (ARE.N: Quote, Profile, Research, Stock Buzz) have issued stock to strengthen their balance sheets.
AMB rose 13.3 percent, or $2.09, to $17.86 and Alexandria closed up 8.7 percent, or $3.35, at $41.76. (Reporting by Ilaina Jonas; editing by Jeffrey Benkoe and Carol Bishopric)
© Thomson Reuters 2009.
Viele Werte haben, obwohl sie bis Ende Dezember 2008 und seit Beginn der US-Immokrise bis zu 80% an Marktkapitalisierung verloren haben, teilweise bis Anfang März 2009 noch mal 30-50% abgegeben.
Verrückte kranke shice.
Der führende US-Shopping Center Entwickler Kimco, ist am Freitag und nach einem upgrade von sell auf hold durch S&P Analyst Robert McMillan, mit +25,5% unter extrem hohem Volumen geradezu explodiert
und hat somit die gesamte REIT Branche nach oben gezogen.Reit Index + 9.1 percent.
Man muss jedoch das Schlachthausniveau beachten .... Derzeit mit 2,5 Milliarden Dollar MK noch der grösste in der Branche (Bereich Shopping Center)
Kimco 9,40 + 25,50
Weingarten
11,33
Simon Properties 41,30
Boston Properties mit einem interssanten Chart
41,69
desgleichen AMB Properties
17,86
Pro Logis als weltweit grösster Logistic Space Entwickler und Betreiber dürfte auch wieder drehen . kommt von 60 Dollar !!!
Equity Residential 21,67
UPDATE 2-Strong demand for Kimco shares raises REITs
Fri Apr 3, 2009 6:17pm EDT
* Strong demand prompts company to boost offering
* Shares rise 25.5 percent
* REIT Index up 9.1 percent.
By Ilaina Jonas
NEW YORK, April 3 (Reuters) -
Shares of shopping center owner Kimco Realty Corp KIM.N closed up 25.5 percent on Friday after strong demand for its stock offering prompted the company to increase the number of shares offered, lifting the badly beaten real estate investment trust (REIT) sector.
Kimco sold 91.5 million shares, up from the previously expected 70 million, after demand was stronger than expected. The shares were offered at $7.10 each.
After the close of the market, the company said its underwriters exercised an option to sell an additional 13.725 million shares, up from the previously planned 10.5 million over-allotment,
The credit crisis has pummeled REIT stocks, with investors concerned that the companies may not be able to refinance their sizable debts when they mature.
After falling 41.5 percent last year, the benchmark MSCI U.S. REIT Index .RMZ was down another 29.9 percent before Friday's pop of 9.1 percent.
"The market is seeing that the capital markets aren't closed," Raymond James analyst R.J. Milligan said. "It's a positive in the fact that investors are still willing to inject capital into REITS (real estate investment trusts).
All together, the offering is expected to net Kimco $717.3 million, to repay debt and for general corporate purposes.
Kimco shares rose $1.91 to close at $9.40 on the New York Stock Exchange, where they were among the top 10 percentage gainers. The company has a stake in about 1,950 properties in 45 U.S. states, Puerto Rico, Canada, Mexico and South America.
S&P analyst Robert McMillan raised his rating on Kimco shares to "hold" from "sell," early in the morning, based in part on the cash expected to be raised from the equity offering.
The optimism was contagious as shares of most property REITs rose.
Developers Diversified Realty CorpDDR.N closed at $2.71 cents, up 14.4 percent, or 34 cents. Macerich Co MAC.N closed up 22.4 percent, or $1.80 at $9.84. Pennsylvania Real Estate Investment Trust (PEI.N: Quote, Profile, Research, Stock Buzz) rose 18.4 percent, or 76 cents, to $4.90.
Boston Properties Inc BXP.N rose 12.4 percent, or $4.59 at $41.69 Federal Realty Investment Trust FRT.N rose $2 or 4.1 percent to close at $50.81. Simon Property Group Inc SPG.N rose 11.7 percent, or $4.33, to $41.30.
The net proceeds from the offering, along with its $394 million in cash and securities and about $1 billion available on its credit facility at the end of 2008, gives Kimco a leg up on meeting its $1.3 billion in debt maturities this year and next, McMillan said.
In the debt-constrained market, several other REITs such as AMB Property Corp (AMB.N: Quote, Profile, Research, Stock Buzz), Simon, and Alexandria Real Estate Equities Inc (ARE.N: Quote, Profile, Research, Stock Buzz) have issued stock to strengthen their balance sheets.
AMB rose 13.3 percent, or $2.09, to $17.86 and Alexandria closed up 8.7 percent, or $3.35, at $41.76. (Reporting by Ilaina Jonas; editing by Jeffrey Benkoe and Carol Bishopric)
© Thomson Reuters 2009.
Research in Motion :shock:
Was für ein fettes gap
03-Apr-09 Upgrade Deutsche Securities Sell → Hold $30 → $56
03-Apr-09 Upgrade Credit Suisse Underperform → Neutral $61
03-Apr-09 Upgrade CIBC Wrld Mkts Sector Perform → Sector Outperform
03-Apr-09 Upgrade BMO Capital Markets Market Perform → Outperform
03-Apr-09 Reiterated RBC Capital Mkts Outperform $75 → $80
03-Apr-09 Reiterated Oppenheimer Outperform $50 → $70
03-Apr-09 Reiterated Kaufman Bros Hold $50 → $64
03-Apr-09 Reiterated Global Crown Capital Overweight $59 → $95
Price 59.29 Change 20.78%
Was für ein fettes gap
03-Apr-09 Upgrade Deutsche Securities Sell → Hold $30 → $56
03-Apr-09 Upgrade Credit Suisse Underperform → Neutral $61
03-Apr-09 Upgrade CIBC Wrld Mkts Sector Perform → Sector Outperform
03-Apr-09 Upgrade BMO Capital Markets Market Perform → Outperform
03-Apr-09 Reiterated RBC Capital Mkts Outperform $75 → $80
03-Apr-09 Reiterated Oppenheimer Outperform $50 → $70
03-Apr-09 Reiterated Kaufman Bros Hold $50 → $64
03-Apr-09 Reiterated Global Crown Capital Overweight $59 → $95
Price 59.29 Change 20.78%
GNTA
0,0098 US$ long
0,0098 US$ long
MMPI sieht sehr geil aus !
SGIC hab ich mich gestern zu 0,20$ nicht getraut, jetzt 0,49$.
GNTA heute ebenfalls mal ansehen
SGIC hab ich mich gestern zu 0,20$ nicht getraut, jetzt 0,49$.
GNTA heute ebenfalls mal ansehen
US:GNTA | News
Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense® in Advanced Melanoma
Genta Incorporated (OTCBB: GNTA.OB) announced that the Company had completed patient enrollment into AGENDA, a Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. Final accrual totaled 315 subjects.
“Completion of this trial represents a major milestone for our Company,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Over the past 10 years, Genta has made a sustained and substantial commitment toward improving health and outcomes for patients with this devastating illness. This timely completion of accrual is a tribute to the hard work of our employees, physician investigators, study coordinators, patients, and families. Their enthusiasm and the extensive prior data that underlay the planning of this trial offers what we believe is the most promising and exciting advance in melanoma therapy after many decades of setbacks. We currently project that the final assessment of progression-free survival (PFS) will be analyzed approximately 6 months after the last patient has been enrolled. If positive, we plan discussions with global regulatory agencies regarding submissions for marketing approval based on this result coupled with our extensive prior data.”
About AGENDA
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study was designed to confirm certain safety and efficacy results obtained in a prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.
Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:
Endpoint
Genasense/DTIC
DTIC
Hazard
Ratio
P
Overall response 20.8% 7.2% 0.002
Durable response 10.7% 2.4% 0.007
Progression-free survival, median 3.6 mos.
1.6 mos.
0.58 < 0.0001
Overall survival, median 12.3 mos.
9.9 mos.
0.64 0.0009
A scientific publication that describes overall efficacy and safety results from the prior study (GM301) can be accessed at: http://jco.ascopubs.org/cgi/content/full/24/29/4738. The co-primary endpoints of AGENDA are progression-free survival (PFS) and overall survival.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
SAFE HARBOR
Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense® in Advanced Melanoma
Genta Incorporated (OTCBB: GNTA.OB) announced that the Company had completed patient enrollment into AGENDA, a Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. Final accrual totaled 315 subjects.
“Completion of this trial represents a major milestone for our Company,” said Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “Over the past 10 years, Genta has made a sustained and substantial commitment toward improving health and outcomes for patients with this devastating illness. This timely completion of accrual is a tribute to the hard work of our employees, physician investigators, study coordinators, patients, and families. Their enthusiasm and the extensive prior data that underlay the planning of this trial offers what we believe is the most promising and exciting advance in melanoma therapy after many decades of setbacks. We currently project that the final assessment of progression-free survival (PFS) will be analyzed approximately 6 months after the last patient has been enrolled. If positive, we plan discussions with global regulatory agencies regarding submissions for marketing approval based on this result coupled with our extensive prior data.”
About AGENDA
AGENDA is a Phase 3, randomized, double-blind, placebo-controlled trial that is intended to support global registration of Genasense for patients with advanced melanoma. The study was designed to confirm certain safety and efficacy results obtained in a prior randomized trial of Genasense combined with dacarbazine (DTIC) in patients who have not previously received chemotherapy (GM301). AGENDA employs a biomarker to define those patients who derived maximum clinical benefit during the preceding study. These patients are characterized by low-normal levels of LDH (lactate dehydrogenase), a tumor-derived enzyme that is readily detected in blood.
Analysis of those efficacy outcomes in GM301, which were observed in 274 patients, showed the following results:
Endpoint
Genasense/DTIC
DTIC
Hazard
Ratio
P
Overall response 20.8% 7.2% 0.002
Durable response 10.7% 2.4% 0.007
Progression-free survival, median 3.6 mos.
1.6 mos.
0.58 < 0.0001
Overall survival, median 12.3 mos.
9.9 mos.
0.64 0.0009
A scientific publication that describes overall efficacy and safety results from the prior study (GM301) can be accessed at: http://jco.ascopubs.org/cgi/content/full/24/29/4738. The co-primary endpoints of AGENDA are progression-free survival (PFS) and overall survival.
About Genasense
Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.
SAFE HARBOR
0,0127$
[url=http://peketec.de/trading/viewtopic.php?p=632732#632732 schrieb:
Amer Security
RAMR heute sehr schick!
bei JNIP kommt Volumen rein
